Conatus Pharmaceuticals (Conatus Pharmaceuticals) Total Stockholders Equity : $17.64 Mil (As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals Total Stockholders Equity?

Conatus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2020 was $17.64 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Conatus Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2020 was $0.53. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Conatus Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2020 was 0.01.

Conatus Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Conatus Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conatus Pharmaceuticals Total Stockholders Equity Chart

Conatus Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Stockholders Equity

Get a 7-Day Free Trial

34.54

21.79

28.00

27.40

20.19

Conatus Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Total Stockholders Equity	Get a 7-Day Free Trial															23.60	24.11	22.00	20.19	17.64

Conatus Pharmaceuticals (NAS:CNAT) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Conatus Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2020 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(17.642	-	0)	/	33.17
	=	0.53

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Conatus Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2020 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.229	+	0)	/	17.642
	=	0.01

Conatus Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Conatus Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127

Website

https://www.conatuspharma.com

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.